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Abstract
The aim of the present work was to develop and characterize two different nanosystems, nanospheres and nanocapsules, containing either
xanthone (XAN) or 3-methoxyxanthone (3-MeOXAN), with the final goal of improving the delivery of these poorly water-soluble
compounds. The xanthones-loaded nanospheres (nanomatrix systems) and nanocapsules (nanoreservoir systems), made of poly(DL-lactide-
co-glycolide) (PLGA), were prepared by the solvent displacement technique. The following characteristics of nanoparticle formulations were
determined: particle size and morphology, zeta potential, incorporation efficiency, thermal behaviour, in vitro release profiles and physical
stability at 4 8C. The nanospheres had a mean diameter !170 nm, a narrow size distribution (polydispersity index !0.1), and a negative
surface charge (zeta potential !K36 mV). Their incorporation efficiencies were 33% for XAN and 42% for 3-MeOXAN. The presence of
the xanthones did not affect the nanospheres size and zeta potential. DSC studies indicated that XAN and 3-MeOXAN were dispersed at a
molecular level within the polymeric nanomatrix. Nanocapsules were also nanometric (mean size !300 nm) and exhibited a negative charge
(zeta potential !K36 mV). Their incorporation efficiency values (O77%) were higher than those corresponding to nanospheres for both
xanthones. The release of 3-MeOXAN from nanocapsules was similar to that observed for the correspondent nanoemulsion, indicating that
drug release is mainly governed by its partition between the oil core and the external aqueous medium. In contrast, the release of XAN from
nanocapsules was significantly slower than from the nanoemulsion, a behaviour that suggests an interaction of the drug with the polymer.
Nanocapsule formulations exhibited good physical stability at 4 8C during a 4-month period for XAN and during a 3-month period for
3-MeOXAN.
q 2004 Elsevier B.V. All rights reserved.
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Xanthones are natural, semisynthetic and totally syn-
thetic heterocyclic compounds with the dibenzo-g-pyrone
framework. Xanthone molecules having a variety of
substituents on the different carbons of the nucleus
constitute a group of compounds with a broad spectrum of0939-6411/$ - see front matter q 2004 Elsevier B.V. All rights reserved.
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E-mail address: mauricio.barbosa@anf.pt (C.M. Barbosa).biological activities [1,2]. Among others, anti-inflammatory
[3], hepatoprotective [4], immunomodulatory [5–7], mod-
ulatory activity of PKC isoforms [8,9] and antitumor
activities of the growth of human cancer cell lines [7].
The poor aqueous solubility of xanthone (XAN)
and of many of its derivatives such as 3-methoxyxanthone
(3-MeOXAN) (Fig. 1) is a major drawback not only for their
use in the therapy but even for the in vitro assessment of
their biological activity. One approach to overcome the
difficulty of administration of poorly water-soluble com-
pounds is their incorporation in polymeric nanocarriers
[10–12]. Depending on the processing conditions, eitherEuropean Journal of Pharmaceutics and Biopharmaceutics 59 (2005) 491–500www.elsevier.com/locate/ejpb
Fig. 1. Chemical structure of xanthones: XAN (RZH), 3-MeOXAN
(RZOCH3).
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spheres are matrix-type systems composed of an entangle-
ment of oligomer or polymer units, while nanocapsules are
reservoir-type systems, consisting of an oily core sur-
rounded by a polymer wall. Besides their ability to improve
the delivery of water-insoluble drugs, nanoparticles have
been reported to control drug release [10], to reduce drug-
associated adverse effects [14], to protect the compounds
from inactivation before reaching their site of action [15], to
increase the intracellular penetration [16] and enhance the
pharmacological activity [12].
Based on these considerations, the aim of the present
work was to develop new formulations of XAN and 3-
MeOXAN consisting of PLGA nanospheres and nanocap-
sules with the final goal of improving the biological
activities of these compounds. The evaluation of the activity
of these molecules, such as the inhibitory effect on nitric
oxide (NO) production from macrophages and the inhibitory
activity on different human cancer cell lines growth,
represents a major interest of our research group.
PLGA was selected for the preparation of the nanocarriers
because of its adequate biocompatibility and biodegrad-
ability [17]. Both systems, nanospheres and nanocapsules
were prepared according to the solvent displacement
technique described by Fessi et al. [18,19]. This is a simple
method that is particularly useful for the encapsulation of
lipophilic substances [13,20,21]. Formulations were charac-
terized with regard to their particle size distribution, zeta
potential, drug incorporation efficiency and thermal beha-
viour. In vitro drug release and stability studies were also
performed for the most promising formulations.2. Materials and methods2.1. Materials
Xanthone (XAN), PLGA (50:50) MW 50 000–75 000,
Pluronic F-68, phosphate buffered saline tablets and
soybean lecithin (40% purity by thin-layer chromatography)
were purchased from Sigma-Aldrich Quı´mica (Sintra,
Portugal). Threalose dihydrate was purchased from Fluka
(Sintra, Portugal). 3-Methoxyxanthone (3-MeOXAN) was
synthesised in our laboratory according to Fernandes et al.[22]. Myritol 318 (caprilic/capric acid triglyceride) was
kindly supplied by Henkel (Lisboa, Portugal). HPLC-grade
methanol and acetonitrile were obtained from Merck
(Lisboa, Portugal). Water was purified by reverse osmosis
Milli-Q system (Milliporew, Lisboa, Portugal). Other
chemicals were of analytical grade.
2.2. Preparation of nanospheres
Nanospheres containing XAN or 3-MeOXAN were
prepared by the solvent displacement technique described
by Fessi et al. [18]. Briefly, an organic solution of PLGA
(63 mg) and different amounts of XAN or 3-MeOXAN
in acetone (10 mL) was poured, under moderate
magnetic stirring, into 10 mL of an aqueous solution of
Pluronicw F-68 0.25% (w/v). Following 5 min of stirring,
the volume of nanosphere dispersion was concentrated to
10 mL under reduced pressure. Separation of non-encapsu-
lated compounds was performed by centrifugation at
2000!g for 30 min. (Heraeus Sepatec centrifuge, Porto,
Portugal) after solubilization of a certain amount of
threalose dihydrate for achieving a 5% (w/v) concentration.
The supernatant was discarded and the pellet containing the
nanospheres was redispersed in water to complete the initial
volume of nanosphere dispersion submitted to centrifu-
gation. Empty nanospheres were prepared according to the
same procedure but omitting the xanthones in the organic
phase.
2.3. Physicochemical characterization of nanospheres
2.3.1. Particle size and zeta potential
Particle size analysis of nanospheres was performed by
photon correlation spectroscopy (PCS). This technique
yields the mean particle diameter and the polydispersity
index (PI), which is a dimensionless measure of the
broadness of the particle size distribution. Zeta potential
was evaluated by laser Doppler anemometry (LDA). In both
determinations, samples were analysed following appro-
priate dilution with filtered (0.22 mm) ultrapure water, using
a Zetasizer 3000 (Malvern Instruments, Malvern, UK).
Values reported are the meanGSD of at least three different
batches of each nanosphere formulation.
2.3.2. Quantification of XAN and 3-MeOXAN content
in nanospheres
The content of XAN and 3-MeOXAN of the nanospheres
was determined by UV (Schimadzu UV 1603 spectropho-
tometer, Shimadzu Co., Kyoto, Japan) at 237 nm, by a
modification of a previously validated method [23],
following the dissolution of the nanospheres in acetonitrile.
Previous studies demonstrated no absorbance interference
from empty nanospheres under the same conditions.
Incorporation efficiency was calculated as follows:
I:E:ð%Þ Z A=B!100
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the nanosphere dispersion and B is the theoretical drug
concentration (mg/mL).
2.3.3. Differential scanning calorimetry (DSC)
DSC was performed in order to characterize the
physical state of XAN and 3-MeOXAN in nanospheres.
Thermograms were obtained using a Shimadzu DSC-50
(Shimadzu Co., Kyoto, Japan). The adopted scanning
temperature range was from 25 to 300 8C at a heating rate
of 10 8C/min.
2.3.4. Morphological studies
Morphological examination of nanospheres was per-
formed by transmission electron microscopy (TEM) (Zeiss
microscope M-10C, New York, USA) following negative
staining with uranyl acetate solution (1%, w/v) or
phosphotungstic acid solution (2%, w/v).
2.4. Preparation of nanocapsules
XAN and 3-MeOXAN-containing PLGA nanocapsules
were prepared by the interfacial polymer deposition
technique described by Fessi et al. [19]. Briefly, about
50 mg of polymer and 100 mg of soybean lecithin were
dissolved in 10 mL of acetone. Different amounts of XAN
or 3-MeOXAN were dissolved in 0.5–0.6 mL of Myritolw
318 and the solution obtained was added to the previously
prepared acetonic solution. The final solution was poured
into 20 mL of an aqueous solution of Pluronicw F-68 0.5%
(w/v) under moderate stirring, leading to the formation of
the nanocapsules. Then, acetone was removed under
vacuum and the colloidal dispersion of nanocapsules was
concentrated to 5–10 mL by evaporation under reduced
pressure. The amount of non-encapsulated xanthones (either
XAN or 3-MeOXAN) was separated by ultrafiltration/
centrifugation technique [19] using centrifugal filter
devices (Centricon YM-50, Milliporew, Lisboa, Portugal)
at 4000!g for 2 h (Beckman UL-80 ultracentrifuge,
Albertville, USA). Empty nanocapsules were prepared
according to the same procedure but omitting the xanthones
in the organic phase.
XAN and 3-MeOXAN nanoemulsions were prepared
as nanocapsules, omitting the polymer in the organic
phase.
2.5. Physicochemical characterization of nanocapsules
2.5.1. Particle size and zeta potential
Particle size analysis of nanocapsules was performed
by photon correlation spectroscopy (PCS). This technique
yields the mean particle diameter and the polydispersity
index (PI), which is a dimensionless measure of the
broadness of the particle size distribution. Zeta potential
was evaluated by laser Doppler anemometry (LDA). In
both determinations, samples were analysed followingappropriate dilution with filtered (0.22 mm) ultrapure
water, using a Zetasizer 5000 (Malvern Instruments,
Malvern, UK). Values reported are the meanGSD of at
least three different batches of each nanocapsule
formulation.2.5.2. Quantification of XAN and 3-MeOXAN content
in nanocapsules
The content of XAN and 3-MeOXAN of the nanocap-
sules was determined by a previously validated HPLC
method [24], following the dissolution of an aliquot of the
nanocapsule dispersion in acetonitrile.
Incorporation efficiency was calculated as described for
nanospheres (Section 2.3.2).2.5.3. In vitro release studies of XAN and 3-MeOXAN
from nanocapsules
In vitro release studies of XAN and 3-MeOXAN from
the nanocapsules were carried out at 37 8C, by the bulk
equilibrium reverse dialysis bag technique, as previously
described by Levy and Benita [25]. Briefly, for each
xanthonic compound, a volume of a nanocapsule dis-
persion—corresponding to 20% of the maximum aqueous
solubility of each compound in phosphate buffered saline
solution 0.1 M, pH7.4 (PBS) at 37 8C—or an aqueous
solution, was placed directly into 200 mL of PBS, where
numerous dialysis sacs (cellulose membrane Mw cut-off
12 000 D, Sigma-Adrich Quı´mica, Sintra, Portugal) con-
taining 1 mL of PBS, had been previously immersed. The
dialysis sacs were equilibrated with PBS prior to the
experiments. At given time intervals, a dialysis bag was
withdrawn from the stirred release medium and the XAN
or 3-MeOXAN content was directly assayed by a
modification of a previously validated HPLC method
[24], setting the detection wavelength at 240 nm. XAN or
3-MeOXAN stock solutions in acetonitrile were diluted
with PBS to obtain calibration solutions over the range of
0.1–1.4 mg/mL. Values reported are the meanGSD of the
values corresponding to three different batches of each
formulation of nanocapsules.2.5.4. Physical stability
The effect of storage time on the particle size and zeta
potential of XAN and 3-MeOXAN-containing nanocap-
sules formulations was assessed. Nanocapsules aqueous
dispersions were stored in sealed glass bottles at 4 8C and
protected from light, during a 4-month period.2.5.5. Morphological studies
The morphology of nanocapsules was assessed by TEM
using a Zeiss EM-10C microscope (New York, USA),
following negative staining with phosphotungstic acid
solution (2%, w/v).
Table 1
Encapsulation parameters of XAN and 3-MeOXAN in PLGA nanospheres
Theoretical
concen-
tration
(mg/mL)
XAN nanospheres 3-MeOXAN nanospheres
Final con-
centration
(mg/mL)
Encapsula-
tion effi-
ciency (%)
Final con-
centration
(mg/mL)
Encapsula-
tion effi-
ciency (%)
50 13.0G1.1 26.1G2.1 19.0G0.6 38.1G1.1
60 20.0G2.4 33.0G4.1 24.9G4.6 41.5G7.6
70 Crystals of
XAN
ND Crystals of
3-MeOXAN
ND
80 Crystals of
XAN
ND Crystals of
3-MeOXAN
ND
Values express the mean resultsGSD values of three different batches. ND,
not determined.
Table 2
Mean diameter, polydispersity index (PI) and zeta potential (z) of PLGA
empty and loaded nanospheres
Empty
nanospheres
XAN
nanospheresa
3-MeOXAN
nanospheresb
Diameter (nm) 154G6 164G8 164G9
PI 0.06G0.03 0.06G0.03 0.06G0.01
z (mV) K36.2G5.2 K38.9G1.3 K36.0G3.0
Values express the mean resultsGSD values of three different batches.
a XAN nanosphere with theoretical concentration of 60 mg/mL.
b 3-MeOXAN nanospheres with theoretical concentration of 60 mg/mL.
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nanospheres
The loading capacity of the nanospheres was assessed
using fixed amounts of polymer and surfactant and variable
quantities of XAN or 3-MeOXAN. According to the results
shown in Table 1, maximum incorporation efficiencies were
achieved either for XAN (33.0G4.1%) or for 3-MeOXAN
(41.5G7.6%) corresponding to a theoretical concentration
of 60 mg/mL. For concentrations above 70 mg/mL both
xanthones precipitated in the form of crystals, indicating
that the maximum loading capacity of the carrier
was reached. Thus, for the theoretical concentration of
60 mg/mL, the final concentrations of encapsulatedFig. 2. Transmission electron microphotographs of PLGA nanospherescompounds were only of 20 mg/mL for XAN and 25 mg/
mL for 3-MeOXAN. According to Barichello et al. [26]
when the drug has a low affinity for the polymer, it tends to
diffuse from the organic phase to the external aqueous
medium during the nanosphere formation process, leading
to low drug loading capacities. The relatively low
association efficiency observed in the present study for
XAN and 3-MeOXAN, suggests that these compounds have
low affinity for the polymer. In fact, for the theoretical
concentration of 60 mg/mL, the final concentrations
achieved for encapsulated compounds were only of 20 and
25 mg/mL for XAN and 3-MeOXAN, respectively. Never-
theless, the nanosphere aqueous dispersions developed
show higher concentrations for both xanthones than the
respective aqueous solutions. Indeed the water-solubility of
both xanthones is about 5–6 mg/mL at 25 8C (data not
shown).
Particle size results (Table 2) of prepared empty XAN
and 3-MeOXAN nanospheres showed that all samples were
in the nanometric range (mean diameter !170 nm) and
exhibited a narrow size distribution (PI!0.1). These results
were confirmed by TEM analysis. In fact, TEM micro-
photographs of XAN- and 3-MeOXAN-loaded nanospheres
(Fig. 2) show their spherical shape as well as their
homogeneous size distribution. Similar results have been
previously reported for PLGA nanoparticles containing
various drugs [26].
Zeta potential results (Table 2) showed that both empty
and drug-loaded nanosphere formulations exhibited
a negative charge with values ranging from K38.9 to
K36.0 mV, typically observed for these types of systems
[27]. The surface charge of colloidal particles can arise by a
number of means, e.g. ionisation of chemical groups on the
surface or adsorption of ions [28]. It has been previously
reported [29,30] that the negative charge of PLGA
nanoparticles is due to the ionisation of carboxylic-end
groups of polymer on the surface. However, carboxylic end
groups of the PLGA used in this study were esterified with
lauryl groups and hence were not susceptible to ionisation.
Thus, the negative charge of prepared nanoparticles can be
attributed to the adsorption of anions on the colloidal
surface. The presence of both xanthones did notcontaining: (A) XAN or (B) 3-MeOXAN. Scale barZ150 nm.
Fig. 3. DSC thermograms of threalose, physical mixture of XAN and empty
PLGA nanospheres (1:1), XAN, PLGA and XAN-loaded nanospheres
(XAN nps).
Fig. 4. DSC thermograms of threalose, physical mixture of 3-MeOXAN and
empty PLGA nanospheres (1:1), 3-MeOXAN, PLGA and 3-MeOXAN-
loaded nanospheres (3-MeOXAN nps).
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potential of nanospheres (PO0.05).
Fig. 3 shows the DSC thermograms corresponding to the
following samples: PLGA; XAN; threalose; a physical
mixture of XAN and empty nanospheres (1:1) and XAN-
loaded nanospheres. The PLGA thermogram displays an
endotherm at 46 8C, corresponding to the polymer glass
transition temperature (Tg) and the threalose thermogram
shows an endotherm attributed to the dehydration of the
compound, which occurred at 98 8C. The thermogram of
XAN displays a thermal event at 178 8C, attributed to its
melting point. Physical mixture of XAN and empty
nanospheres (1:1) exhibits endotherms corresponding to
the Tg of PLGA, to the dehydration of threalose as well as to
the melting point of XAN. For XAN-loaded nanospheres a
thermal event at 98 8C, attributed to threalose crystal
dehydration was observed and it was not possible to clearly
identify whether the polymer Tg has suffered any significant
change. Furthermore, since no XAN melting endotherm was
observed we might conclude that there are no crystalline
XAN domains in nanospheres.Fig. 4 shows DSC thermograms corresponding to the
following samples: PLGA; 3-MeOXAN; threalose; physi-
cal mixture of 3-MeOXAN and empty nanospheres (1:1)
and 3-MeOXAN-loaded nanospheres. The thermogram of
3-MeOXAN shows a thermal event at 131 8C correspond-
ing to its melting point. The physical mixture of 3-
MeOXAN and empty PLGA nanospheres exhibits
endotherms corresponding to the Tg of PLGA, to the
dehydration of threalose as well as to the melting point of
3-MeOXAN. The thermogram of 3-MeOXAN-loaded
nanospheres shows an endotherm corresponding to threa-
lose dehydration (at 98 8C) and a mild thermal event at
approximately at 46 8C, which may correspond to the Tg of
the polymer. However, the melting endotherm of 3-
MeOXAN was not detected. Consequently, these data
suggest that both XAN and 3-MeOXAN form a molecular
dispersion in the polymer matrix of nanospheres.3.2. Characteristics of XAN and 3-MeOXAN-loaded
nanocapsules
Two strategies were adopted in order to prepare stable
nanocapsule dispersions containing a high concentration of
both xanthones. One of them was based on increasing the
concentration of xanthones added to the oily core of the
nanocapsules until the precipitation of the excess — non-
encapsulated — occurred and could be observed. For this
Table 3
Encapsulation parameters of XAN and 3-MeOXAN in PLGA nanocapsules
XAN nanocapsules 3-MeOXAN nanocapsules
Theoretical
concentration
(mg/mL)
XAN/
Myritol
318%
(w/v)
Final concen-
tration (mg/mL)
Encapsulation
efficiency (%)
Theoretical
concentration
(mg/mL)
3-MeOXAN/
Myritol
318%
(w/v)
Final concen-
tration (mg/mL)
Encapsulation
efficiency (%)
200 0.4 178G21 89G11 1000 2.0 887G51 89G5
400 0.8 342G18 85G5 1200 2.4 918G9 77G1
600 1.2 529G57 88G9 1400 2.8 1162G80 83G6
700 1.4 Crystals of XAN ND 1600 3.2 Crystals of
3-MeOXAN
ND
800 1.6 Crystals of XAN ND
Values express the mean resultsGSD values of three different batches. ND, not determined.
Table 4
Mean diameter, polydispersity index (PI) and zeta potential (z) of empty
and loaded PLGA nanocapsules
Empty
nanocapsules
XAN
nanocapsulesa
3-MeOXAN
nanocapsulesb
Diameter (nm) 274G3 278G15 280G19
PI 0.455G0.130 0.412G0.051 0.376G0.104
z (mV) K40.9G5.9 K39.1G0.7 K39.5G4.7
Values express the mean resultsGSD values of three different batches.
a XAN nanocapsules with theoretical concentration of 600 mg/mL.
b 3-MeOXAN nanocapsules with theoretical concentration of
1400 mg/mL.
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capsules were prepared using fixed amounts of polymer
(PLGA), surfactants (Pluronic F-68 and soybean lecithin)
and 0.5 mL of oil and increasing theoretical concentrations
of xanthones in the final suspension ranging from 200 to
800 mg/mL for XAN and from 1000 to 1600 mg/mL for
3-MeOXAN. The resulting incorporation efficiency values
were close to 90% for XAN formulations with theoretical
concentrations ranging from 200 to 600 mg/mL (Table 3).
For higher concentrations, XAN crystals could be observed,
indicating that the maximum loading capacity of the
nanocapsules had been reached. For the 3-MeOXAN-loaded
nanocapsules, the incorporation efficiency values were close
to 80% for theoretical concentrations ranging from 1000 to
1400 mg/mL. As in the previous case, for higher concen-
trations, 3-MeOXAN crystals could be detected. Hence,
maximum concentrations of xanthones encapsulated into
the nanocapsules were attained for theoretical concen-
trations of 600 mg/mL for XAN (corresponding to a
concentration of 1.2%, w/v, in Myritol 318) and 1400 mg/
mL for 3-MeOXAN (corresponding to a concentration of
2.8%, w/v, in Myritol 318). According to different authors
[31–33], the percentage of drug encapsulated in the
nanocapsules is correlated to the drug solubility in the oil
core. In the present case, the incorporation efficiency values
of both xanthones were relatively close. However, the final
concentration of the nanoencapsulated 3-MeOXAN
(1162 mg/mL) was higher than that of XAN (529 mg/mL).
An explanation for these results may be the higher solubility
of 3-MeOXAN in Myritol 318 than XAN.
The second strategy adopted in order to increase the con-
centration of the nanoencapsulated xanthones in the
nanocapsules suspension was based on increasing the
volume of Myritol 318 and on concentrating the final
dispersion to 5 mL instead of 10 mL. When using this
strategy, one must be aware of the fact that, as observed by
Guterres et al. [31] for PLA nanocapsules containing
diclofenac, the increase of the oil volume can eventually
reduce the stability of nanocapsules. More specifically, these
authors found that the use of a volume of oil (benzylbenzo-
ate) higher than 0.75 mL (corresponding to a concentrationof 5%, v/v), led to the formation of unstable nanocapsules
with the appearance of a precipitate and free oil. A common
method used to study the stability of nanocapsules is the
ultracentrifugation [34,35]. When nanocapsule dispersions
prepared with an oil core with a density !1, such as Myritol
318, are submitted to centrifugation four possible phases can
be detected. One is constituted by a small pellet attributed to
the formation of nanospheres due to the inadequate polymer
deposition at the interfacial level. An additional phase may
be found containing surfactants and non-encapsulated
compounds. A floating cream layer corresponding to stable
nanocapsules constitutes the third one. Finally, an oily phase
may appear at the surface of the preparation due to oil drops
that coalesced when surfactants could not stabilize the
preparation.
In the present work, to study the stability of nanocapsules
prepared with high oil volumes (O0.5 mL), several
formulations of empty nanocapsules were obtained using
fixed amounts of polymer and surfactants and different
volumes of Myritol 318 (0.5, 0.6, 0.7 and 0.8 mL) and
submitted to centrifugation (25 000!g, for 30 min). The
formulations containing 0.5 and 0.6 mL of Myritol 318
showed a small pellet at the bottom of the flask, attributed to
nanospheres and a cream layer at the surface corresponding
to nanocapsules. No free oil could be detected in these
formulations indicating that the oil was completely coated
by the polymer. The formulations including 0.7 and 0.8 mL
of Myritol 318 showed a free oil layer at the surface of the
dispersions upon centrifugation indicating a poor stability.
Table 5
Mean diameter, polydispersity index (PI), zeta potential (z) and incorporation parameters of various nanocapsule formulations: empty nanocapsules (0.6 mL
Myritol 318 and without xanthones), XAN-loaded nanocapsules (0.6 mL Myritol 318, XAN theoretical concentration of 1440 mg/mL) and 3-MeOXAN-loaded
nanocapsules (0.6 mL Myritol 318, 3-MeOXAN theoretical concentration of 3360 mg/mL)
Sample Theoretical con-
centration (mg/mL)
Final concentration
(mg/mL) [n]
Encapsulation
efficiency (%)
Diameter (nm) [n] PI z (mV) [n]
Empty nanocapsules – – – 261G17 [5] 0.48G0.06 K36.3G4.3 [5]
XAN nanocapsules 1440 1173G100 [7] 82G7 273G18 [5] 0.48G0.05 K36.4G9.3 [5]
3-MeOXAN
nanocapsules
3360 2780G238 [7] 83G7 271G16 [5] 0.43G0.03 K41.8G5.4 [5]
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of Myritol 318 that allows the preparation of stable
nanocapsule formulations. As a consequence, the new
formulations of XAN and 3-MeOXAN-containing nano-
capsules were prepared using 0.6 mL of Myritol 318, while
maintaining the concentration of each compound in the oil
volume (1.2%, w/v, for XAN and 2.8%, w/v, for 3-
MeOXAN). This led to concentrations of nanoencapsulated
XAN and 3-MeOXAN in the final dispersions of
1173 mg/mL and of 2780 mg/mL, respectively. Thus, the
nanocapsule aqueous dispersions developed show higher
concentrations for both xanthones than the respective
aqueous solutions as well as the nanosphere dispersions.
Results of particle size analysis (Tables 4 and 5) indicate
that the mean sizes of the different nanocapsule formu-
lations are lower than 300 nm and correspond to a mid-
range polydispersity population (PI!0.5). TEM analysis
confirmed these results and showed the spherical mor-
phology of XAN and 3-MeOXAN nanocapsules (Fig. 5).
Similar particle size results have been previously reported
for PLGA nanocapsules containing phenylbutazone [36].
Furthermore, the results show that the mean particle size
values of XAN or 3-MeOXAN-loaded nanocapsules do not
differ significantly (PO0.05) from those corresponding to
empty nanocapsules.
Zeta potential results (Tables 4 and 5) show that both
empty and drug-loaded nanocapsules, exhibit a negative
charge with values ranging from K41.8 to K36.3 mV. The
presence of xanthones did not affect significantly the zeta
potential (PO0.05). Negative zeta potential values of
K41 mV have also been previously reported by Marchal-
Heussler et al. [37] for PLGA nanocapsules containingFig. 5. Transmission electron microphotographs of PLGA nanocapsulebetaxolol. The zeta potential values of the nanocapsules
developed in our study may constitute an important
contribution for the physical stability of the dispersions. In
fact, it is known that high zeta potential values, above
30 mV, either positive or negative, lead to more stable
nanocapsule dispersions due to the repulsion between
particles, which prevents their aggregation [20]. Our results
can be attributed to the specific composition of the
nanocapsules (polymer and surfactant concentrations as
well as to the type of oil core). According to several authors
[20,35,38], the major components of nanocapsules, which
can affect their zeta potential are lecithins, oil core, polymer
and poloxamer. Lecithins and oils have compounds such as
free acids or negatively charged phospholipids, which
confer a negative charge to nanocapsules. Polymers,
especially poly a-hydroxy acids, such as poly(DL-lactide),
impart negative charge due to carboxyl groups. Poloxamer,
a non-ionic surfactant, tends to reduce the absolute value of
zeta potential.
3.3. In vitro release
The in vitro release profiles of 3-MeOXAN and of XAN
from PLGA nanocapsules and from the corresponding
control nanoemulsions are shown in Figs. 6 and 7.
Nanoemulsions were used as control, in order to investigate
the role of polymeric wall on drug release. These figures
also show the corresponding release diffusion profiles of the
free compounds in aqueous solution through the dialysis
bag. The experiments were performed under ‘sink con-
ditions’, in order to avoid the interference of the xanthones
solubility in the in vitro release. As can be observed in boths containing: (A) XAN or (B) 3-MeOXAN. Scale barZ250 nm.
Fig. 6. In vitro release profiles of 3-MeOXAN from PLGA nanocapsules
and from nanoemulsion followed by its diffusion through the dialysis bag.
The diffusion profile of free 3-MeOXAN dissolved in the medium through
the dialysis membrane is shown as a control. The theoretical 3-MeOXAN
concentration was, in nanocapsules and nanoemulsion, 3360 mg/mL. Each
point represents the meanGSD values obtained from three different
batches. The inset shows the release profiles over the first 8 h (*P!0.05).
Fig. 8. Evolution of mean size of empty nanocapsules, XAN- and 3-
MeOXAN-loaded nanocapsules, during storage at 4 8C for 4 months.
M. Teixeira et al. / European Journal of Pharmaceutics and Biopharmaceutics 59 (2005) 491–500498figures, practically the totality of both xanthones in solution
diffused through the dialysis bag within 4 h. However, when
the xanthones were either nanoencapsulated or incorporated
into nanoemulsions, the amounts diffused to the inner side
of the dialysis bag were reduced, as was also found by other
authors for different substances [33,39].
As can be seen in Fig. 6, the release of 3-MeOXAN from
nanocapsules and nanoemulsions yielded similar profiles. In
both cases, an important initial release rate of the compound
during the first hour and a slower release rate up to the fourthFig. 7. In vitro release profiles of XAN from PLGA nanocapsules and from
nanoemulsion followed by its diffusion through the dialysis bag. The
diffusion profile of free XAN dissolved in the medium through the dialysis
membrane is shown as a control. The theoretical XAN concentration was,
in nanocapsules and nanoemulsion, 1440 mg/mL. Each point represents the
meanGSD values obtained from three different batches. The inset shows
the release profiles over the first 8 h (*P!0.05).hour were observed. At 1 h of the experiment, the mean
amounts of 3-MeOXAN released from nanoemulsion
and nanocapsule dispersion were approximately 70% and
at 4 h were roughly 80%. Identical release profiles were
already reported for other drugs [33,35,36]. The similarity
of the release profiles obtained for both systems in the
present study evidences that the polymer coating of
nanocapsules has no role in the release process of
3-MeOXAN, being the compound’s partition between the
oily core and the external aqueous medium the main factor
governing the process, as was already reported for other
drugs [35,36,40].
As can be seen in Fig. 7, the release of XAN from
nanocapsules and nanoemulsions yielded different profiles.
Despite the important initial release observed for both
systems, a significant difference (P!0.05) after the first
30 min and up to the end of the experiment was noted. At
30 min, the mean amounts of XAN released from
nanocapsule and nanoemulsion dispersions were
59.7G4.3% and 69.0G2.5%, respectively. At 4 h. and
until the end of the assay, the mean amounts of XAN
released from nanocapsule and nanoemulsion dispersions
were approximately 70 and 80%, respectively. The different
release profiles indicates that another factor besides XAN
partition between oil core and the aqueous mediumFig. 9. Evolution of zeta potential of empty nanocapsules, XAN- and 3-
MeOXAN-loaded nanocapsules, during storage at 4 8C for 4 months.
M. Teixeira et al. / European Journal of Pharmaceutics and Biopharmaceutics 59 (2005) 491–500 499influences the release from nanocapsules, which may
suggest the existence of an interaction between the
compound and the polymer of the nanocapsules. Indeed,
as previously reported for other drugs [33], the slower
release from the nanocapsules as compared to the emulsion
could be attributed to an interaction between the compound
and the polymer wall of the nanocapsules.
By comparing the release profiles of both xanthones from
the respective nanoemulsions (Figs. 6 and 7), the afore-
mentioned higher affinity of 3-MeOXAN for Myritol 318 is
in accordance with its slower release rate.
The rapid release of different drugs from nanocapsules
has been previously reported by different authors [20].
Despite this large burst release, nanocapsules have been
shown to improve biological activities of several drugs
either in vitro [41] or in vivo when administered by ocular
[37] or parenteral [42] routes. Therefore, besides nano-
capsule formulations we developed afforded higher
concentrations of XAN and 3-MeOXAN than those
corresponding to the respective aqueous solutions, these
nanocarriers could also be useful for the improvement of
biological activity of xanthones.
3.4. Physical stability
Particle size is an important property of colloidal
dispersions, since the tendency to sediment is determined
by changes in this parameter [43]. Furthermore, particle size
influences their in vivo behaviour [44]. As shown in Fig. 8,
no significant differences (PO0.05) on the mean size of
empty nanocapsules and XAN- or 3-MeOXAN-loaded
nanocapsules were observed during storage of the respective
aqueous dispersions at 4 8C for 4 months. Similarly, no
significant variation on zeta potential values (Fig. 9) was
observed during storage for all studied nanocapsule
formulations (PO0.05).
Besides the lack of changes in size or zeta potential, the
xanthone-loaded nanocapsules remained visually
unchanged during storage in the referred conditions. No
sediment, cream or free oil could be observed in any
formulation. In addition, no XAN crystals were observed for
up to 4 months. For 3-MeOXAN-loaded nanocapsules no
crystals were detected for up to 3 months. However, some
crystals could be observed at the end of the fourth month.
Guterres et al. [31] and Schaffazick et al. [45] have also
reported the appearance of drug crystals in nanocapsule
formulations during storage (after 8 months). According to
these authors, this phenomenon could be attributed to
the presence of nanocrystals, stabilized by the surfactants,
which, with time, start to grow and precipitate.4. Conclusions
The solvent displacement technique adopted in the
present work was found to be appropriate for the preparationof nanoparticle formulations containing either XAN or
3-MeOXAN. This process allowed us to obtain nanospheres
of a mean diameter !170 nm and nanocapsules of a mean
diameter !300 nm. Nanoincorporation of these poorly
water-soluble compounds affords the preparation of formu-
lations with higher concentrations of XAN or 3-MeOXAN
than those corresponding to the respective aqueous
solutions. Nanocapsules appear to be more appropriate
carriers for both xanthones, once encapsulated XAN and
3-MeOXAN concentrations in the final dispersions were 60
and 100-fold, respectively, to those corresponding to
nanospheres. 3-MeOXAN release from nanocapsules is
governed mainly by its partition between the oil core and the
external aqueous medium. The release profile of XAN from
nanocapsules suggests the existence of an interaction of the
drug with the polymer. Developed nanocapsule formu-
lations were shown to be physically stable for a period of
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